Currently, drugs that activate both PPARα and PPARγ such as gliatazars, or selective modulators of PPARs such as pemafibrate for PPARα, are being developed as T2DM and antiatherosclerotic therapy, respectively, and appear to have better results [36]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.